FRAT1 Polyclonal Antibody, PE-Cy7 Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-12434R-PE-Cy7 |
| Product Name | FRAT1 Polyclonal Antibody, PE-Cy7 Conjugated |
| Applications |
WB
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow |
| Specifications | |
| Conjugation | PE-Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human FRAT1 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 10023 |
| Subcellular location | Cytoplasm |
| Synonyms | FRAT 1; frequently rearranged in advanced T cell lymphomas; Frequently rearranged in advanced T-cell lymphomas; GSK 3 binding protein FRAT1; proto oncogene FRAT1; FRAT1_HUMAN. |
| Background | FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma, and they have since been identified as proto-oncogenes involved in tumorigenesis. These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) binding protein, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development. Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway. Wnt signaling is regulated in part by the activity of GSK-3, which phosphorylates and thereby facilitates the degradation of ?catenin. GBP binds to GSK-3 and inhibits this phosphorylation, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes. Like GBP, FRAT2 has been shown to bind xGSK-3, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins. |
| Application Dilution | |
| WB | 1:300-5000 |